Search results for "Acute"

showing 10 items of 2516 documents

Antipoxvirus Activity Evaluation of Optimized Corroles Based on Development of Autofluorescent ANCHOR Myxoma Virus

2021

International audience; A series of 43 antiviral corrole-based molecules have been tested on myxoma virus (Lausanne-like T1MYXV strain). An autofluorescent MYXV, with an ANCHOR cassette, has been used for the studies. A(2)B-fluorocorroles display various toxicities, from 40 being very toxic (CC50 = 1.7 mu M) to nontoxic 38 (CC50 > 50 mu M), whereas A(3)-fluorocorroles, with one to three fluorine atoms, are not toxic (with the exception of corroles 9, 10, and 22). In vitro, these compounds show a good selectivity index when used alone. Corrole 35 seems to be the most promising compound, which displays a high selectivity index with the lowest IC50. Interestingly, this "Hit" corrole is easy to…

0301 basic medicinePorphyrins[SDV]Life Sciences [q-bio]030106 microbiologyresistant strainMyxoma virusAntiviral Agents03 medical and health scienceschemistry.chemical_compoundmyxoma viruscorroleIn vivoAnimalsCorroleIC50Strain (chemistry)biologybiology.organism_classificationantiviralAcute toxicityIn vitro3. Good healthdsDNA virus030104 developmental biologyInfectious DiseaseschemistryBiochemistrypoxvirusRabbitsSelectivity
researchProduct

The Culpability of Respiratory Viruses in Pneumonia-Related Acute Respiratory Failure

2018

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industrymedia_common.quotation_subject030106 microbiologyMEDLINECritical Care and Intensive Care Medicinemedicine.disease03 medical and health sciencesPneumonia0302 clinical medicineJurymedicineAcute respiratory failure030212 general & internal medicineRespiratory systemCardiology and Cardiovascular MedicineIntensive care medicinebusinessmedia_commonCulpabilityChest
researchProduct

Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

2021

Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Much of these diseases burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that with respect to low density lipoprotein cholesterol (LDL-C), “lower is better for longer”, and the recent data have strongly emphasized the need of also “the earlier the better”. In addition to statins, which have been available for several decades, the availability of ezetimibe and inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) are additional very effective approa…

0301 basic medicineRMmedicine.medical_specialtyCombination therapyPCSK9 inhibitoreffectivenessTreatment goalsLipid-lowering therapy03 medical and health sciences0302 clinical medicineEzetimibemedicineHumansAcute Coronary SyndromeCombination therapyIntensive care medicinePharmacologyStatins.business.industryAtherosclerotic cardiovascular diseaseAnticholesteremic AgentsPCSK9StatinsEffectiveneDisease ManagementAtherosclerosisEzetimibeLipids030104 developmental biologyPCSK9 inhibitors030220 oncology & carcinogenesisPosition paperSafetybusinessVery high riskmedicine.drug
researchProduct

Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublis…

2018

Zofenopril is a lipophilic, sulfhydryl group-containing angiotensin-converting enzyme (ACE)-inhibitor, characterized by wide tissue distribution, long duration of action, and pleiotropic effects on endothelial dysfunction. Its clinical efficacy and safety have been described in the four randomized controlled trials of the SMILE program, which globally enrolled more than 3600 patients in post-acute myocardial infarction (AMI) setting. The SMILE-4 study specifically selected patients with left ventricular dysfunction at admission, and compared the effects of zofenopril or ramipril in combination with acetylsalicylic acid (ASA). Zofenopril demonstrated its superiority over ramipril in reducing…

0301 basic medicineRamiprilmedicine.medical_specialtyCaptoprilPopulationMyocardial InfarctionCardiologyAngiotensin-Converting Enzyme InhibitorsHeart failureReviewAcute myocardial infarction030204 cardiovascular system & hematologylaw.inventionZofenopril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineAcute myocardial infarction; Angiotensin-converting enzyme inhibitors; Cardiology; Heart failure; Left ventricular dysfunction; Ramipril; Zofenopril; Pharmacology (medical)MedicineHumansPharmacology (medical)Myocardial infarctioneducationRandomized Controlled Trials as Topiceducation.field_of_studyLeft ventricular dysfunctionEjection fractionbusiness.industryGeneral Medicinemedicine.diseaseZofenopril030104 developmental biologyTreatment OutcomechemistryAngiotensin-converting enzyme inhibitorHeart failureCardiologyNumber needed to treatbusinessmedicine.drug
researchProduct

Nuclear Factor Kappa B Signaling Complexes in Acute Inflammation.

2020

[Significance]: Nuclear factor kappa B (NF-κB) is a master regulator of the inflammatory response and represents a key regulatory node in the complex inflammatory signaling network. In addition, selective NF-κB transcriptional activity on specific target genes occurs through the control of redox-sensitive NF-κB interactions.

0301 basic medicineRedox signalingPhysiologyClinical BiochemistryRepressorCREBInteractomeBiochemistry03 medical and health sciencesCoactivatorHumansSTAT3Transcription factorMolecular BiologyGeneral Environmental ScienceInflammation030102 biochemistry & molecular biologybiologyChemistryActivator (genetics)NF-kappa BCell Biology3. Good healthCell biology030104 developmental biologyGene Expression RegulationMultiprotein ComplexesAcute DiseaseSTAT proteinbiology.proteinGeneral Earth and Planetary SciencesDisease SusceptibilitySignaling complexesCarrier ProteinsBiomarkersProtein BindingSignal TransductionAntioxidantsredox signaling
researchProduct

The interactions between host glycobiology, bacterial microbiota, and viruses in the gut

2018

Rotavirus (RV) and norovirus (NoV) are the major etiological agents of viral acute gastroenteritis worldwide. Host genetic factors, the histo-blood group antigens (HBGA), are associated with RV and NoV susceptibility and recent findings additionally point to HBGA as a factor modulating the intestinal microbial composition. In vitro and in vivo experiments in animal models established that the microbiota enhances RV and NoV infection, uncovering a triangular interplay between RV and NoV, host glycobiology, and the intestinal microbiota that ultimately influences viral infectivity. Studies on the microbiota composition in individuals displaying different RV and NoV susceptibilities allowed th…

0301 basic medicineRotavirus030106 microbiologylcsh:QR1-502MicrobiologiaReviewBiologymedicine.disease_causelcsh:MicrobiologyMicrobiology03 medical and health sciencesSecretorAntigenstomatognathic systemVirologyRotavirusHisto-blood group antigens (HBGAs)medicineAnimalsHumansGlycomicsInfectivityGlycobiologyHost (biology)MicrobiotaNorovirusAcute gastroenteritisGastroenteritisVirusGastrointestinal Tract030104 developmental biologyInfectious DiseasesHost susceptibilityHost-Pathogen InteractionsFucosyltransferase-2 gene (FUT2)NorovirusReceptors VirusMicrobiota composition
researchProduct

Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib

2017

IL-6 is a central mediator of the immediate induction of hepatic acute phase proteins (APP) in the liver during infection and after injury, but increased IL-6 activity has been associated with multiple pathological conditions. In hepatocytes, IL-6 activates JAK1-STAT3 signaling that induces the negative feedback regulator SOCS3 and expression of APPs. While different inhibitors of IL-6-induced JAK1-STAT3-signaling have been developed, understanding their precise impact on signaling dynamics requires a systems biology approach. Here we present a mathematical model of IL-6-induced JAK1-STAT3 signaling that quantitatively links physiological IL-6 concentrations to the dynamics of IL-6-induced …

0301 basic medicineRuxolitinibruxolitinibPhysiologySystems biologyRegulatorBiologyPharmacology: Biochemistry biophysics & molecular biology [F05] [Life sciences]lcsh:Physiology03 medical and health sciencesMediatoracute phase responsePhysiology (medical)medicineSOCS3primary hepatocytes: Biochimie biophysique & biologie moléculaire [F05] [Sciences du vivant]Original ResearchIL-6lcsh:QP1-981Acute-phase proteinmathematical modelingJAK-STAT signaling pathwayCell biology030104 developmental biologySignal transductionmedicine.drugFrontiers in Physiology
researchProduct

HLA and killer cell immunoglobulin-like receptor (KIRs) genotyping in patients with acute viral encephalitis

2018

// Antonino Tuttolomondo 1 , Claudia Colomba 2 , Danilo Di Bona 6 , Alessandra Casuccio 4 , Domenico Di Raimondo 1 , Giuseppe Clemente 1 , Valentina Arnao 5 , Rosaria Pecoraro 1 , Paolo Ragonese 5 , Anna Aiello 3 , Giulia Accardi 3 , Rosario Maugeri 5 , Carlo Maida 1 , Irene Simonetta 1 , Vittoriano Della Corte 1 , Domenico Gerardo Iacopino 5 , Calogero Caruso 3 , Antonio Cascio 2 and Antonio Pinto 1 on behalf of KIRIIND (KIR Infectious and Inflammatory Diseases) Collaborative Group 1 U.O.C di Medicina Interna con Stroke Care, Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S), Universita degli Studi di Palermo, Palermo, Italy 2 U.O.C di Malattie Infettive, Dipartiment…

0301 basic medicineSettore MED/09 - Medicina InternaencephalitisKiller-cell immunoglobulin-like receptorHuman leukocyte antigenAcute viral encephalitis03 medical and health sciences0302 clinical medicineEncephalitimedicineIn patientGenotypingSettore MED/04 - Patologia Generalebusiness.industryHaplotypemedicine.diseaseVirologyKIRHLA030104 developmental biologyEncephalitis; HLA; KIRs; OncologyOncologybusinessKIR3DL1KIRs030217 neurology & neurosurgeryEncephalitisResearch Paper
researchProduct

Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients

2021

COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA COVID-19 vaccine (N = 1256). For each participant, socio-demographic data, COVID-19 vaccination records, serological analyses, and SARS-CoV-2 infection status were collected. IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Almost all vaccinated subjects (99.8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% of vaccinated subjects had IgG concentrations &gt

0301 basic medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)virusesImmunologyArticleSerologyPersistence (computer science)03 medical and health sciences0302 clinical medicineAntigenDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicineskin and connective tissue diseasesPharmacologyantibody concentrations.biologybusiness.industryImmunogenicitySARS-CoV-2 infectionfungiRantibody concentrationsrespiratory tract diseasesVaccinationbody regions030104 developmental biologyInfectious DiseasesImmunizationImmunologybiology.proteinMedicineAntibodybusinessCOVID-19 vaccineVaccines
researchProduct

Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.

2021

Coronavirus disease 2019 (COVID-19) is a major threat worldwide due to its fast spreading. As yet, there are no established drugs available. Speeding up drug discovery is urgently required. We applied a workflow of combined in silico methods (virtual drug screening, molecular docking and supervised machine learning algorithms) to identify novel drug candidates against COVID-19. We constructed chemical libraries consisting of FDA-approved drugs for drug repositioning and of natural compound datasets from literature mining and the ZINC database to select compounds interacting with SARS-CoV-2 target proteins (spike protein, nucleocapsid protein, and 2′-o-ribose methyltransferase). Supported by…

0301 basic medicineSimeprevirArtificial intelligencevirusesMERS Middle East Respiratory SyndromeHealth InformaticsBiologyMachine learningcomputer.software_genremedicine.disease_causeAntiviral AgentsArticleWHO World Health OrganizationAUC area under the curve03 medical and health sciences0302 clinical medicinessRNA single-stranded RNA virusmedicineChemotherapyHumansSARS severe acute respiratory syndromeCOVID-19 coronavirus disease 2019CoronavirusNatural productsVirtual screeningACE2 angiotensin converting enzyme 2Drug discoverybusiness.industrySARS-CoV-2COVID-19LBE lowest binding energyFDA Food and Drug AdministrationROC receiver operating characteristicComputer Science ApplicationsHIV human immunodeficiency virusMolecular Docking SimulationDrug repositioning030104 developmental biologyDrug developmentSevere acute respiratory syndrome-related coronavirusParitaprevirInfectious diseasesRespiratory virusArtificial intelligenceSupervised Machine Learningbusinesscomputer030217 neurology & neurosurgeryComputers in biology and medicine
researchProduct